- Translation from Thai -

No. Selic 034/2025

Date: November 14, 2025

Subject: Notification of the Increase in Registered Capital of Subsidiaries and the Acquisition of Assets by an Indirect Subsidiary

To: The President
The Stock Exchange of Thailand

SELIC Corp Public Company Limited (the "Company") would like to inform that the Board of Directors' Meeting No. 6/2025, held on November 14, 2025, has passed significant resolutions which can be summarized as follows:

1. Approved the increase of registered capital of Selic Global Venture Co., Ltd. ("SGV"), a subsidiary in which the Company holds 100% of the shares, by Baht 169,060,000 by issuing 1,690,600 new ordinary shares, with a par value of Baht 100 per share. The Board also approved for the Company to subscribe to the said capital increase, using the Company's working capital and/or loans from financial institutions to complete the transaction, with details as follows:

Date of Transaction : Within the first quarter of 2026
Objective : To be used as investment capital
Registered Capital and Paid-up capital

Before Capital Increase	After Capital Increase
Baht 282,500,000, divided into 2,825,000 ordinary shares with a par value of Baht 100 per share.	Baht 451,560,000, divided into 4,515,600 ordinary shares with a par value of Baht 100 per share.

2. Approved the increase of registered capital of Selic Healthcare Co., Ltd. ("SHC"), an indirect subsidiary in which the Company holds 100% of the shares, by Baht 169,060,000, by issuing 1,690,600 new ordinary shares at a par value of Baht 100 per share, with details as follows:

Date of Transaction : Within the first quarter of 2026
Objective : To be used as investment capital
Registered Capital and Paid-up capital

Before Capital Increase	After Capital Increase
Baht 282,500,000, divided into 2,825,000 ordinary shares with a par value of Baht 100 per share.	Baht 451,560,000, divided into 4,515,600 ordinary shares with a par value of Baht 100 per share.

In this regard, the transaction above is not deemed as connected transactions under the Notification of the Capital Market Supervisory Board No. Tor.Jor.21/2551 Re: Rules on Connected Transactions, nor an acquisition of assets under the Notification of the Board of governors of the Stock Exchange of Thailand Re: Disclosure of Information and Other Acts of Listed Companies Concerning the Acquisition and Disposition of Assets B.E. 2547 and the Notification of the Capital Market Supervisory Board No. Tor.Jor.20/2551 Re: Rules on Entering into Material Transactions Deemed as acquisition or disposition of assets (as amended) as the transactions are completed between the Company and its subsidiary in which the Company holds shares in the proportion of 100 percent of all shares issued by the subsidiary.

3. Approved that Selic Healthcare Co., Ltd. ("SHC"), an indirect subsidiary, enter into a transaction to acquire 3,207,960 ordinary shares of Devakam Apothecary Hall Co., Ltd. from the existing shareholders, representing 9.39% of the registered and paid-up capital, at a price of Baht 52.70 per share, totaling Baht 169,059,492, with the following details:

3.1 Transaction Date:

The transaction is expected to be completed within the first quarter of 2026

3.2 Counterparties and relation with the Company

Buyer: Selic Healthcare Co., Ltd. (Indirect subsidiary)

Seller: Fertig Pharma Co., Ltd. (Existing shareholder)

Relationship with the Company: The seller has no relationship considered a related party under the Capital Market Supervisory Board Notification No. TorChor. 21/2551 regarding connected transactions and the Stock Exchange of Thailand's disclosure requirements for connected transactions, B.E. 2546, as well as other relevant announcements.

3.3 Type and description of the transaction



Selic Healthcare Co., Ltd. ("SHC"), an indirect subsidiary, will enter into a transaction to acquire 3,207,960 ordinary shares of Devakam Apothecary Hall Co., Ltd. from the existing shareholders, representing 9.39% of the registered and paid-up capital, with a par value of Baht 5 per share, at a purchase price of Baht 52.70 per share, totaling Baht 169,059,492. The purchase price is mutually agreed upon by the buyer and the seller and does not exceed the fair value as appraised by an independent appraiser.

3.4 Details of assets

Company Name	Devakam Apothecary Hall Co., Ltd. ("DVK") (Indirect subsidiary, with 50% shareholding)
Acquired Assets:	Ordinary shares of Devakam Apothecary Hall Co., Ltd. ("DVK"), totaling 3,207,960 shares, representing 9.39% of the registered and paid-up capital
Head Office Location	12/571 Moo.15, Soi Sornhirun, Bangna-Trad Road, Bangkaew Subdistrict, Bang Phli District, Samut Prakan Province
Company Registration Date	January 7, 1946
Registered and Paid-up Capital	Baht 170,774,180, divided into 34,154,836 ordinary shares with a par value of Baht 5 per share
Business Type	Manufacturing and distribution of muscle pain relief products under the brand "Muay," sold both domestically and internationally.
Board of Directors	1. Pol. Lt. Gen. Thongtuch Intratat 2. Mr. Athavudhi Hirunburana 3. M.L. Thirachet Sonakul 4. Mr. Ek Suwatthanaphim 5. Mr. Supawat Likittanawong 6. Col. Thosprom Intratat 7. Mrs. Angeli Suwatthanaphim 8. Mrs. Sethaporn Sundaravibata 9. Ms. Nida Thiengtham 10. Mr. Teerawat Tilokskulchai 11. Mr. Chanin Apiradee
Relationship with the Company	Selic Healthcare Co., Ltd. ("SHC") and Devakam Apothecary Hall Co., Ltd. ("DVK") are indirect subsidiaries of the Company.

Shareholding Structure Before and After Selic Healthcare Co., Ltd. ("SHC") Acquires Ordinary Shares of Devakam Apothecary Hall Co., Ltd. ("DVK") is as follows:

Shareholders	Before Transaction		After Transaction	
	Shares	%	Shares	%
1. New Diamond Holdings PTE Ltd.	8,214,923	24.05	8,214,923	24.05
2. Fertig Pharma Co., Ltd.	7,552,140	22.11	4,344,180	12.72
3. Selic Healthcare Co., Ltd.	17,077,418	50.00	20,285,378	59.39
4. Others (Management)	1,310,355	3.84	1,310,355	3.84
Total	**34,154,836**	**100**	**34,154,836**	**100**

3.5 Total Consideration and Payment Terms

The purchase of 3,207,960 ordinary shares of Devakam Apothecary Hall Co., Ltd., representing 9.39% of the registered and paid-up capital, with a par value of Baht 5 per share, at a purchase price of Baht 52.70 per share, amounts to Baht 169,059,492.

Selic Healthcare Co., Ltd. ("SHC"), as the buyer, will pay the purchase price to the seller within the first quarter of 2026.

3.6 Criteria for Determining the Value of Assets and Calculation of Transaction Size

The transaction qualifies as an acquisition of assets by the listed company under the Capital Market Supervisory Board Notification No. TorChor. 20/2551 regarding the criteria for significant transactions that constitute the acquisition or disposition of assets (including amendments), and the Stock Exchange of Thailand's Notification on Disclosure and Procedures of Listed Companies for Acquisition or Disposal of Assets B.E. 2547 (including amendments) ("Acquisition or Disposal Notification"). The transaction size is calculated based on the asset acquisition criteria, referencing the consolidated financial statements for the nine-month period ended September 30, 2025, of the Company and DVK, with details as follows:

(Unit : Million baht)

Item	The Company	("DVK")
Total Assets	3,177.85	963.88
<u>Less</u> Intangible Assets	1,063.96	317.17
<u>Less</u> Total Liabilities	1,429.81	448.34
<u>Less</u> Non-controlling Interests (if any)	526.49	-
Net Tangible Assets (NTA)	157.59	198.37
Profit Attributable to Owner (Last 4 Quarters)	136.11	91.72

Calculation of transaction size according to the acquisition or disposal notification using all four criteria, the details are as follows:

(Unit : Million baht)

Criterion	Calculation		Transaction Size (%)
1. Net Tangible Assets (NTA)	(NTA of the investment × proportion acquired or disposed) ÷ NTA of the listed company × 100	$\frac{198.37x9.39\%}{157.59}$	11.82
2. Net Profit	(Net profit from operations of the investment × proportion acquired or disposed) ÷ Net profit of the listed company × 100	$\frac{91.72x9.39\%}{136.11}$	6.33
3. Total consideration	(Consideration paid or received ÷ Total assets of the listed company) × 100	$\frac{169.06x100}{3177.85}$	5.32
4. Shares Issued to Pay for Assets	(No. of shares issued to pay for the assets ÷ Paid-up shares of the listed company) × 100	Not applicable (no shares were issued)	

The above-mentioned transaction is not considered a connected transaction, but qualifies as an acquisition of assets. The transaction size is 11.82%, calculated based on the Net Tangible Assets (NTA) criterion, which represents the highest transaction value. This calculation references the consolidated financial statements for the nine-month period ended September 30, 2025, of the Company and DVK. When combined with other asset acquisitions within the past six months, the cumulative transaction size is 11.85%, based on the highest calculated criterion. Since this is below 15%, the Company is not required to report information under the Acquisition or Disposal of Assets Notification.

3.7 Source of Funds

The funds used for the transaction will come from the proceeds received from the capital increase.

3.8 Expected Benefits

The purpose of this investment is to enable the Company to acquire increased control and oversight over the management of the DVK group, which will allow the Company to make decisions, plan strategies, and set the business direction of DVK more effectively. It is also expected to strengthen the capabilities of the Company's healthcare business in the future. In addition, increasing the shareholding in DVK from 50% to 59.39% will allow the Company to recognize a larger share of profits from DVK's operating results.

3.9 Board of Directors' Opinion on the Transaction

The Board of Directors has considered the details of the transaction and is of the view that the proposed additional acquisition of shares in Devakam Apothecary Hall Co., Ltd. ("DVK") is appropriate and beneficial to the Company and its shareholders. The investment is in a business with a solid foundation, strong growth potential, and aligns with Selic Group's strategy to expand its healthcare and consumer products business.

3.10 Opinion of the Audit Committee and/or any Directors differing from the Board

None

Please be informed accordingly.

Yours sincerely,

(Mr. Narong Suwatthanaphim)

Acting Chief Executive Officer

Selic Corp Public Company Limited
270 Liapkhlongphasicharoen Fungtai Road.
Nongkhaem, Bangkok, Thailand 10160

บริษัท ซีลิค คอร์พ จำกัด (มหาชน)
270 ถนนเลียบคลองภาษีเจริญฝั่งใต้
แขวงหนองแขม กรุงเทพฯ 10160

T +66 2807 3347-9
F +66 2445 5245
W seliccorp.com